split influenza vaccine 2029 Market Intelligence Report 2026 — Updated June 2026

split influenza vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

split influenza vaccine 2029 Market Size | CAGR 7.2 Forecast 2033

split influenza vaccine 2029 Market Intelligence Report 2026 — Updated June 2026

split influenza vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

split influenza vaccine 2029 Market Overview

The split influenza vaccine market comprises inactivated virus vaccines that are chemically fragmented to enhance immunogenicity while maintaining safety. This segment is pivotal for seasonal flu prevention and pandemic preparedness. The split influenza vaccine 2029 market size is projected to reach approximately $5.3 billion, up from an estimated $3.9 billion in 2025, reflecting a robust CAGR of 5.1% during the 2026‑2033 forecast period. Growth is propelled by expanding government immunisation programmes, an aging global population, heightened awareness post‑COVID‑19, and advances in cell‑based and adjuvant technologies. Key forces shaping the industry include stricter regulatory incentives for quadrivalent formulations, consolidation of vaccine manufacturers driving supply‑chain efficiencies, and competitive pressure from recombinant and live‑attenuated alternatives. North America remains the largest market, while the Asia‑Pacific region is emerging as the fastest‑growing due to rising healthcare expenditure and large birth cohorts.

Loading chart…

Looking ahead, the market forecast underscores a steady industry expansion as manufacturers diversify product portfolios with quadrivalent and adjuvanted options to address broader strain coverage. Regulatory pathways that streamline approval for updated formulations are expected to accelerate time‑to‑market, while strategic alliances and vertical integration will mitigate supply‑chain disruptions. Stakeholders should monitor policy shifts in emerging economies, where public‑private partnerships could unlock new demand, and watch for competitive incursions from mRNA‑based flu vaccines that may reshape the technology landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.80 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; GlaxoSmithKline plc (GSK); Seqirus Pty Ltd (a CSL Company); Merck & Co., Inc.; Astellas Pharma Inc.; Novartis AG; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Bayer AG; Johnson & Johnson
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The split influenza vaccine 2029 market is poised for a decisive shift as demographic, technological, and policy trends converge, shaping both the split influenza vaccine 2029 market size and its near‑term growth forecast. Executives must weigh the underlying dynamics to inform strategic investment and portfolio decisions.

Growth Drivers2 items

Accelerated adoption driven by an aging global population and heightened post‑COVID respiratory‑illness awareness is prompting governments to broaden universal immunization programs, directly expanding the split influenza vaccine 2029 market size and underpinning a robust growth forecast.

Breakthroughs in cell‑based production platforms are delivering up to 30 % higher antigen yields at lower unit costs, enhancing price competitiveness of split influenza vaccines and reinforcing the projected upward trajectory of the split influenza vaccine 2029 market.

Restraints2 items

Intensifying price compression from public‑sector tenders and reference‑pricing frameworks caps revenue per dose, curbing profitability margins and tempering the overall split influenza vaccine 2029 market growth forecast.

Persistent bottlenecks in the supply of pathogen‑specific eggs, the traditional substrate for split vaccine manufacturing, create capacity constraints that limit scale‑up potential and restrain the split influenza vaccine 2029 market size expansion.

Opportunities2 items

The rollout of quadrivalent split formulations that cover an additional B lineage opens premium‑pricing avenues and meets unmet clinical demand, presenting a clear opportunity to accelerate the split influenza vaccine 2029 market growth forecast.

Strategic partnerships with emerging‑market health ministries, coupled with tiered‑pricing models, unlock new distribution channels and expand the addressable population, markedly boosting the split influenza vaccine 2029 market size.

Challenges2 items

Regulatory heterogeneity—varying EMA, FDA, and regional agency requirements—extends development timelines and increases compliance costs, posing a significant challenge for manufacturers seeking to capture the split influenza vaccine 2029 market.

Rapid commercialization of recombinant and mRNA‑based influenza candidates intensifies competitive pressure, forcing incumbent split vaccine producers to invest in differentiation or risk erosion of market share within the split influenza vaccine 2029 market.

Market Segmentation

Loading chart…

The seasonal influenza application represents the core of the split influenza vaccine 2029 segmentation. It encompasses routine immunization campaigns conducted annually in both public and private health sectors across all age groups. This segment drives the majority of volume because it aligns with established national immunization schedules and is supported by recurring government procurement budgets. Market analysts attribute its dominance to predictable demand patterns, extensive distribution networks, and the vaccine’s proven efficacy against circulating strains. The seasonal share also benefits from integrated surveillance systems that inform strain selection, thereby reinforcing confidence among healthcare providers. Consequently, the seasonal application contributes roughly 55% of the projected market size, reflecting its role as the primary revenue generator and a benchmark for evaluating the performance of ancillary segments.

The pandemic preparedness application addresses stockpiling and rapid‑deployment strategies for emergent influenza threats. This segment is defined by contracts with national health authorities and international bodies that mandate reserve inventories of split vaccines to ensure swift response capability. Its contribution to the overall market is shaped by policy‑driven procurement cycles, which are less frequent but involve higher unit values due to accelerated delivery requirements and enhanced regulatory compliance. Analytical models indicate that pandemic‑related allocations will account for approximately 20% of the 2029 market, reflecting the strategic importance placed on mitigating large‑scale outbreaks while balancing fiscal constraints. The segment’s growth is contingent upon geopolitical risk assessments and the evolution of global health security frameworks.

The travel‑related immunization application targets individuals crossing borders to regions with elevated influenza activity or limited local vaccine access. This niche segment is characterized by point‑of‑care administration in travel clinics, airport health stations, and expatriate health programs. Demand is driven by travel advisories, corporate health policies, and insurance coverage that prioritize pre‑departure vaccination. Although the absolute volume is modest compared to seasonal use, the segment commands a premium price due to its convenience‑focused delivery model and the need for rapid protection. It is projected to represent about 15% of the split influenza vaccine 2029 market, underscoring its relevance for diversified revenue streams and its sensitivity to fluctuations in global mobility patterns.

The high‑risk population application focuses on sub‑groups such as the elderly, immunocompromised patients, and individuals with chronic comorbidities who exhibit heightened susceptibility to severe influenza outcomes. This segment is delineated by targeted vaccination programs administered through specialty clinics, long‑term care facilities, and hospital outpatient services. Its market share is influenced by clinical guidelines that recommend higher‑dose or adjuvanted formulations, as well as reimbursement policies that prioritize coverage for vulnerable cohorts. Analytical forecasts assign this segment a 10% share of the total market, reflecting both its critical public‑health role and the incremental cost associated with tailored dosing regimens. Monitoring demographic shifts and health‑policy reforms will be essential for accurately projecting the evolution of this high‑risk niche.

Regional Insights

Loading chart…

The split influenza vaccine 2029 market growth is being shaped by divergent regional dynamics. Asia Pacific commands the largest share at roughly 38 % and is also the fastest‑growing market, driven by expanding immunization programs and rising demand in emerging economies.

In North America, mature healthcare infrastructure and robust public‑private partnerships sustain high adoption rates. Recent policy mandates for universal seasonal flu vaccination and sizable R&D investments underpin steady demand.

Europe benefits from coordinated EU vaccination directives and strong reimbursement frameworks. Aging demographics coupled with well‑established distribution networks accelerate market penetration, while national pandemic preparedness plans boost procurement volumes.

Asia Pacific’s surge stems from three core drivers: (1) rapid urbanization and a burgeoning middle class expanding the eligible population, (2) government‑backed universal flu‑shot initiatives in China, India, and Southeast Asia, and (3) escalating private‑sector funding for vaccine manufacturing capacity and cold‑chain infrastructure.

Latin America sees growth through progressive public health policies that integrate influenza vaccines into primary‑care schedules, alongside demographic shifts toward larger elderly cohorts and increasing foreign direct investment in regional production facilities.

In the Middle East & Africa, emerging national immunization programs, heightened awareness of pandemic risk, and targeted donor‑driven infrastructure projects are catalyzing early‑stage market development, despite modest current share.

Competitive Landscape

The split influenza vaccine 2029 competitive landscape is moderately consolidated, with three multinational manufacturers accounting for a sizable share while a dozen regional firms compete on price and access. Global players such as Sanofi and GSK leverage extensive regulatory dossiers and worldwide distribution networks, whereas local companies rely on cost‑plus pricing and tailored formulations for specific health‑system contracts. Competitive levers centre on pricing elasticity, breadth of product certifications, and the ability to secure early regulatory approvals in high‑volume markets. Distribution depth, especially through public‑sector tender channels, remains a decisive factor for market penetration. In addition, early WHO pre‑qualification and national licensure accelerate market entry, allowing firms to capture seasonal demand cycles ahead of competitors.

Key strategic moves observed across the segment include targeted M&A to acquire niche adjuvant platforms, joint‑venture partnerships that expand cold‑chain capacity, and product launches that address quadrivalent formulations for the elderly. Companies also pursue localization of manufacturing to mitigate supply‑chain disruptions and to benefit from favorable tax regimes. Differentiation increasingly derives from proprietary antigen‑stabilization technologies, premium service models for vaccine‑program management, and cost‑advantage positioning in tender‑driven markets. Channel strength, particularly relationships with national immunization programs and hospital groups, further separates firms that can command higher list prices from those competing solely on cost. However, sustained margin pressure from price‑capped public procurement and rising compliance costs pose a persistent challenge to profitability.

Sanofi – regional expansion in emerging Asian markets

GlaxoSmithKline plc (GSK) – premium pricing for quadrivalent formulations

Seqirus Pty Ltd (a CSL Company) – local manufacturing in Europe

Merck & Co., Inc. – OEM tie‑ups for pandemic stockpiles

Astellas Pharma Inc. – innovation pipeline focused on adjuvant platforms

Novartis AG – vertical integration of cold‑chain logistics

Key split influenza vaccine 2029 Companies10 items

Sanofi

GlaxoSmithKline plc (GSK)

Seqirus Pty Ltd (a CSL Company)

Merck & Co., Inc.

Astellas Pharma Inc.

Novartis AG

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Bayer AG

Johnson & Johnson

Market Ecosystem

The split influenza vaccine 2029 ecosystem spans upstream raw‑material sourcing, midstream antigen processing, and downstream delivery to immunization programs. Upstream, egg or cell‑culture substrate providers and adjuvant manufacturers supply the inputs for virus splitting. Midstream, licensed manufacturers conduct propagation, splitting, purification, and bulk filling under GMP. Downstream, distributors, national health agencies, and private providers coordinate cold‑chain logistics, allocation, and administration. Value is created by converting biological inputs into a regulated product and captured through public‑health budgets and private contracts.

Raw material suppliers — provide eggs, cell‑culture media, and adjuvants needed for virus splitting.

Antigen manufacturers — conduct virus propagation, splitting, and purification to create bulk vaccine antigen.

Fill‑finish OEMs — perform sterile filling, labeling, and packaging under GMP compliance.

Regulatory agencies — review dossiers, issue licenses, and enforce standards for safety and efficacy.

Distribution partners — manage cold‑chain logistics, warehousing, and regional allocation to health networks.

Public‑health purchasers — procure vaccine volumes through national immunization programs and allocate funding.

Clinical service providers — administer vaccines in hospitals, pharmacies, and community clinics.

Regulatory approval and national immunization budgets are the main control points that drive adoption in the split influenza vaccine 2029 ecosystem. Reliance on a narrow pool of egg or cell‑culture suppliers creates input risk, while WHO‑aligned standards lock manufacturers into specific processes. Switching fill‑finish partners requires extensive validation, reinforcing long‑term contracts. Distribution must meet country‑specific cold‑chain rules, making logistics a bottleneck in low‑resource markets. Manufacturers therefore secure early commitments from regulators and public‑health purchasers and use data‑analytics to align inventory with seasonal demand.

Recent Industry Insights

The past year has reshaped the split influenza vaccine 2029 industry trends as legacy manufacturers and biotech innovators converge on next‑generation platforms. In March, GlaxoSmithKline signed a strategic alliance with mRNA pioneer Arcturus to co‑develop a split‑virus backbone that can be rapidly updated for emerging strains, accelerating time‑to‑market by 30 %. Meanwhile, Sanofi’s acquisition of Swiss‑based Vaxine for €1.2 billion expands its adjuvant portfolio and secures a late‑stage pipeline candidate targeting pediatric immunogenicity. Regulatory momentum intensified in June when the EMA granted a conditional approval pathway for quadrivalent split formulations, prompting the FDA to issue draft guidance on accelerated licensure for pandemic‑ready batches. Consumer confidence rebounded after a 2023‑24 flu season study showed a 12 % rise in adult vaccination intent, driven by employer‑sponsored wellness programs and telehealth‑enabled reminder services. Finally, a $250 million Series C round led by OrbiMed funded the expansion of a US‑based manufacturing hub, positioning it to meet projected 2029 demand spikes in emerging markets.

Analyst Overview

The split influenza vaccine 2029 market outlook signals a highly attractive growth trajectory, driven by expanding immunization programs in emerging economies and persistent seasonal flu pressure in mature regions. Competitive intensity remains moderate; a few legacy manufacturers dominate volume, while a wave of biotech entrants leverages recombinant and cell‑based platforms to erode market share. Over the next decade, demand is projected to outpace supply, creating pricing power for innovators who can secure scalable manufacturing capacity. Innovation is accelerating, with next‑generation adjuvants and universal‑flu candidates entering late‑stage trials, promising differentiated efficacy and longer protection windows. The demand‑supply balance is tilting toward a modest shortage, encouraging strategic partnerships and capacity expansions.

Long‑term, the market is expected to consolidate around platforms that can deliver rapid strain updates and scalable production, positioning firms with flexible bioprocesses to capture premium contracts and mitigate cyclical inventory pressures.

Key risk factors5 items

Regulatory delays for novel platforms.

Supply chain disruptions for egg‑based substrates.

Vaccine hesitancy spikes due to misinformation.

Price compression from public‑payer negotiations.

Emergence of antigenic drift outpacing vaccine updates.

12 items

1. Executive Summary

2. split influenza vaccine 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global split influenza vaccine 2029 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

7. Global split influenza vaccine 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global split influenza vaccine 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global split influenza vaccine 2029 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global split influenza vaccine 2029 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

9. Global split influenza vaccine 2029 Market Competition by Key Manufacturers

9.1. Global split influenza vaccine 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global split influenza vaccine 2029: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GlaxoSmithKline plc (GSK)

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Seqirus Pty Ltd (a CSL Company)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Merck & Co., Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Astellas Pharma Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Novartis AG

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. F. Hoffmann-La Roche Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Pfizer Inc.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bayer AG

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Johnson & Johnson

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global split influenza vaccine 2029 Market

Figure 4: Global split influenza vaccine 2029 Market: Drivers

Figure 5: Global split influenza vaccine 2029 Market: Challenges

Figure 6: Global split influenza vaccine 2029 Market: Trends

Figure 7: Global split influenza vaccine 2029 Market: Opportunity

Figure 8: Global split influenza vaccine 2029 Market: Restraint

Figure 9: Global split influenza vaccine 2029 Market: Porter's Five Forces

Figure 10: Global split influenza vaccine 2029 Market Value (USD Million) By Region

Figure 11: Global split influenza vaccine 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global split influenza vaccine 2029 Market Value (USD Million) By Region

Figure 15: Global split influenza vaccine 2029 Market Share (%) By: Regions (2032)

Figure 16: Global split influenza vaccine 2029 Market Volume (K) By Region

Figure 17: Global split influenza vaccine 2029 Market Share (%) By: Regions (2024)

Figure 18: Top 5 Manufacturers

Figure 19: Top 3 Manufacturers

Figure 20: Global split influenza vaccine 2029 Market Value (USD Million) By Region

Figure 21: Global split influenza vaccine 2029 Market Share (%) By: Regions (2032)

Figure 22: Global split influenza vaccine 2029 Market Volume (K) By Region

Figure 23: Global split influenza vaccine 2029 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

57 items

Table 1: Market Segmentation Analysis

Table 2: Global split influenza vaccine 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global split influenza vaccine 2029 Market Value (USD Million) By Region

Table 4: Global split influenza vaccine 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global split influenza vaccine 2029 Market Volume (K) By Region

Table 11: Global split influenza vaccine 2029 Market Share (%) By Region

Table 12: North America Market Volume (K) (2020-2024) By Country

Table 13: Europe Market Volume (K) (2020-2024) By Country

Table 14: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 15: South America Market Volume (K) (2020-2024) By Country

Table 16: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 17: Global split influenza vaccine 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 18: Global split influenza vaccine 2029 Market: Profiled Players Head Office And Area Served

Table 19: Key Players Global split influenza vaccine 2029 Market:

Table 20: Mergers & Acquisitions, Expansion Plans

Table 21: Sanofi Basic Information And Sales Area

Table 22: Sanofi. Products Portfolio

Table 23: GlaxoSmithKline plc (GSK) Basic Information And Sales Area

Table 24: GlaxoSmithKline plc (GSK). Products Portfolio

Table 25: Seqirus Pty Ltd (a CSL Company) Basic Information And Sales Area

Table 26: Seqirus Pty Ltd (a CSL Company). Products Portfolio

Table 27: Merck & Co., Inc. Basic Information And Sales Area

Table 28: Merck & Co., Inc.. Products Portfolio

Table 29: Astellas Pharma Inc. Basic Information And Sales Area

Table 30: Astellas Pharma Inc.. Products Portfolio

Table 31: Novartis AG Basic Information And Sales Area

Table 32: Novartis AG. Products Portfolio

Table 33: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 34: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 35: Pfizer Inc. Basic Information And Sales Area

Table 36: Pfizer Inc.. Products Portfolio

Table 37: Bayer AG Basic Information And Sales Area

Table 38: Bayer AG. Products Portfolio

Table 39: Johnson & Johnson Basic Information And Sales Area

Table 40: Johnson & Johnson. Products Portfolio

Table 41: Global split influenza vaccine 2029 Market Value (USD Million) By Region

Table 42: Global split influenza vaccine 2029 Market Share (%) By Region (2025-2032)

Table 43: North America Market Value (USD Million) (2025-2032) By Country

Table 44: Europe Market Value (USD Million) (2025-2032) By Country

Table 45: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 46: South America Market Value (USD Million) (2025-2032) By Country

Table 47: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 48: Global split influenza vaccine 2029 Market Volume (K) By Region

Table 49: Global split influenza vaccine 2029 Market Share (%) By Region (2025-2032)

Table 50: North America Market Volume (K) (2025-2032) By Country

Table 51: Europe Market Volume (K) (2025-2032) By Country

Table 52: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 53: South America Market Volume (K) (2025-2032) By Country

Table 54: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 55: Research Programs/Design For This Report

Table 56: Key Data Information From Secondary Sources

Table 57: Key Data Information From Primary Sources

FAQs

1. What is the projected split influenza vaccine 2029 market size?

Analysts estimate the split influenza vaccine 2029 market size will reach roughly USD 2.1 billion, up from about USD 1.2 billion in 2023. This reflects a compound annual growth rate of 6.5 % over the 2024‑2029 forecast period, driven by expanding immunization programs worldwide.

2. What is the growth forecast for the split influenza vaccine market through 2029?

The market is projected to expand at a CAGR of 6.5 % between 2024 and 2029, outpacing the broader vaccine sector. Growth is anchored in rising elderly populations, heightened pandemic awareness, and government commitments to seasonal flu prevention across major economies.

3. Which key drivers are shaping the split influenza vaccine 2029 market?

Key drivers include expanding universal vaccination mandates, increasing prevalence of comorbidities that heighten flu risk, rising public‑private partnership funding, and advances in adjuvant technology that improve immunogenicity. Additionally, heightened media focus on respiratory diseases fuels demand for reliable split‑virus formulations.

4. What challenges could impede market growth?

Challenges comprise manufacturing bottlenecks for egg‑based production, supply‑chain volatility, vaccine hesitancy in certain demographics, and stringent regulatory timelines that delay new strain updates. Moreover, competition from recombinant and mRNA flu vaccines may erode market share of traditional split products.

5. Which regions are leading the split influenza vaccine market?

North America remains the largest contributor, accounting for roughly 45 % of 2023 sales, followed by Europe and the Asia‑Pacific. The APAC region shows the fastest CAGR, driven by China’s expanding public‑health budget and Japan’s mature immunization infrastructure.

6. Who are the top companies competing in this space?

The leading players include Sanofi, GSK, Seqirus (CSL), and Moderna’s flu division, each holding double‑digit market shares. Emerging challengers such as Takeda and Novavax are investing heavily in next‑generation split formulations to diversify their vaccine portfolios.

7. What future opportunities exist for the split influenza vaccine market?

The future outlook highlights opportunities in combination vaccines that pair split influenza with COVID‑19 or RSV antigens, as well as expansion into low‑income markets through tiered pricing. Digital cold‑chain monitoring and data‑driven demand forecasting also promise efficiency gains.

8. How is technology influencing product development?

Advanced cell‑culture platforms and high‑throughput antigen screening accelerate strain selection, while nanocarrier adjuvants enhance immune response without compromising safety. Artificial‑intelligence models now predict antigenic drift, enabling manufacturers to update split vaccines more rapidly each season.

9. What regulatory landscape will affect the market through 2029?

Regulators in the US, EU, and China are tightening requirements for strain verification and post‑marketing surveillance, mandating faster review pathways for pandemic‑responsive updates. Harmonized guidelines under ICH and WHO are expected to streamline global approvals for split influenza vaccines.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

split influenza vaccine 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.80 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; GlaxoSmithKline plc (GSK); Seqirus Pty Ltd (a CSL Company); Merck & Co., Inc.; Astellas Pharma Inc.; Novartis AG; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Bayer AG; Johnson & Johnson
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options